Transfer Factor as an Option for Managing the COVID-19 Pandemic
Language English Country Czech Republic Media print
Document type Journal Article, Review
PubMed
33069187
DOI
10.14712/fb2020066030086
PII: file/5926/fb2020a0012.pdf
Knihovny.cz E-resources
- MeSH
- Adjuvants, Immunologic therapeutic use MeSH
- Betacoronavirus MeSH
- COVID-19 MeSH
- Coronavirus Infections immunology therapy MeSH
- Humans MeSH
- Pandemics MeSH
- SARS-CoV-2 MeSH
- Transfer Factor therapeutic use MeSH
- Pneumonia, Viral immunology therapy MeSH
- Research Design MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- Transfer Factor MeSH
Covid-19 or SARS-CoV-2, a new RNA virus with high infectivity, and seemingly low mutability, which appeared in 2019 in the Wuhan province of China, has created a pandemic with dire consequences. At the end of May 2020, it became the first cause of mortality. As no treatment or vaccine may become available before many months, and because occurrence of similar pandemics is only a matter of time, arguments are presented here for testing the effect of transfer factor (TF), an immunomodulator devoid of toxicity, which has been extensively studied in the past for the treatment and prevention of viral infections.
HHV 6 Foundation Santa Barbara CA USA
Immunobiology Laboratory Faculté de Médicine Paris 6 France
Immunotherapy dept S Orsola Malpighi University Hospital Bologna Italy
Medical Oncology S Orsola Malpighi University Hospital Bologna Italy
References provided by Crossref.org
